Biogen (BIIB)
NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-07
$205.70-1.32%
Close 2026-07-07 · 1-day change
Reading BIIB? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track BIIB free→NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-07
Reading BIIB? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track BIIB free→Warn: Management is running behind on a stated commitment.
Biogen manages a mid-single digit revenue decline in 2026. It invests in growth through acquisitions like Apellis and RayThera. Earnings per share are expected around $14.75 in 2026 and $16.63 in 2027. Profit margins remain stable with steady cash flow.
Revenue decline could worsen beyond mid-single digits. Investment in growth may not pay off due to pipeline cuts. Earnings could fall short of $14.25 to $15.25 per share in 2026. Legal and management changes may disrupt execution.
The market expects about 3% revenue growth and prices the stock roughly 26% below our valuation model's midpoint. Our view is more optimistic on earnings growth and successful integration of acquisitions.
Breaks if: FCF yield falls below 8%
Breaks if: EPS falls below $14.25 in FY26 or below $16.63 in FY27
Standing thesis, reviewed periodically — not a price target or advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Significant setbacks or pipeline reductions from acquisitions
Biogen continues to focus on investment for growth, including business development and pipeline expansion.
Breaks if: revenue decline exceeds 5% YoY in FY26
Biogen aims to manage a mid-single digit percentage decline in total revenue for 2026 compared to 2025.
Biogen is managing a projected mid-single digit revenue decline for 2026 compared to 2025.